Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00229125 · ClinicalTrials.gov registry record · Phase 2
Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam
A Phase 2 study, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00229125 is a Phase 2 study that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 160 participants.
The verdict
NCT00229125, a Phase 2 study, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate if the medication Gabapentin, which is not approved for the treatment of alcohol withdrawal, is effective in the treatment of alcohol withdrawal syndrome compared to treatment with Lorazepam.
Interventions
- DRUG Gabapentin
- DRUG Lorazepam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2001-07 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00229125
The ClinicalTrials.gov registry entry for NCT00229125 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gabapentin is the first listed.
NCT00229125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00229125 about?
NCT00229125 is a clinical study titled "Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam". The purpose of this study was to evaluate if the medication Gabapentin, which is not approved for the treatment of alcohol withdrawal, is effective in the treatment of alcohol withdrawal syndrome compared to treatment with Lorazepam.
What is the current status of trial NCT00229125?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2001-07. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00229125?
The interventions under investigation include: Gabapentin (DRUG), Lorazepam (DRUG).
Who is sponsoring clinical trial NCT00229125?
This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.